Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €2.38 EUR
Change Today -0.10 / -4.03%
Volume 116.5K
As of 11:38 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

faes farma sa (FAE) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/12/15 - €2.62
52 Week Low
12/29/14 - €1.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FAES FARMA SA (FAE)

Related News

No related news articles were found.

faes farma sa (FAE) Related Businessweek News

No Related Businessweek News Found

faes farma sa (FAE) Details

Faes Farma, S.A. engages in the research, development, manufacture, market, and sale of pharmaceutical products; and raw materials for pharmaceutical use worldwide. The company offers prescription, OTC, and skin-care treatment products. It provides cardiovascular products, such as Drosmina, Hyflon, Venosmil, Venosmil Gel, and Venula; central nervous system products, including Colme, Surmenalit, and Trausan; dermatology products comprising Positón; digestive products, such as Mecolzine; metabolism products, including Dynamogen, Ferroprotina, and Potenciator; Locomotor products comprising Defal, Distem, Dolotren, and Dolotren gel; Bilaxten and Bilidren for allergy; and respiratory products, such as Bronquidiazina CR and Yendol. The company also offers raw materials, including diosmin, hidrosmin, magnesium pidolate, arginine aspartate, granulated diosmin, glutodine, trimethropim, and pyrrolidone carboxylate. In addition, it develops Bilastine, an antihistamine, which is in Phase III clinical trials; F-97013-GD, an atypical antipsychotic that is in pre-clinical phase; F-98214-TA, an antidepressant, which is in pre-clinical phase; and serotonin reuptake inhibitors. Faes Farma, S.A. was founded in 1933 and is headquartered in Bilbao, Spain.

Founded in 1933

faes farma sa (FAE) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

faes farma sa (FAE) Key Developments

Faes Farma and Eddingpharm Form Joint Venture in China

Faes Farma has signed a deal with Eddingpharm (Hong Kong) for the establishment of a joint venture that allows the Spanish company to market its products in the Chinese market. Under the terms of the agreement, the products will be manufactured in Faes Farma plants and exported to China. The project is being initiated with local development and registration of four Faes Farma products in China.

Faes Farma, S.A., Annual General Meeting, Jun 23, 2015

Faes Farma, S.A., Annual General Meeting, Jun 23, 2015. Location: Avda. Abandoibarra, 4 Bilbao.

Faes Farma, S.A. Announces Earnings Results for the Year Ended December 2014

Faes Farma, S.A. announced earnings results for the year ended December 2014. For the year, the company's total revenues were EUR 198.1 million compared with EUR 193.3 million a year ago. The increase in the company's sales has mainly relied on the revenues obtained from Bilastine's licences linked to the fulfillment of certain milestones, on the positive development of the international business (exports grew by 24%) and animal nutrition, as well as on sales of the products marketed over the last years (specially Bilaxten and the anti-diabetic and anti-inflammatory licences) and the catalogue of mature products. EBITDA was EUR 42.2 million compared with EUR 36.2 million a year ago, helped by the increase in sales and the cost containment. EBIT was EUR 33.3 million compared with EUR 25.8 million a year ago. Profit before tax was EUR 32.8 million compared with EUR 24.2 million a year ago. Net profit was EUR 25.3 million compared with EUR 22.6 million a year ago. As on December 2014, the company's net debt was EUR 21 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FAE:SM €2.38 EUR -0.10

FAE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Recordati SpA €21.23 EUR +0.04
Shire PLC 4,852 GBp -47.00
Procter & Gamble Co/The $68.76 USD -1.17
View Industry Companies

Industry Analysis


Industry Average

Valuation FAE Industry Range
Price/Earnings 20.0x
Price/Sales 2.9x
Price/Book 2.4x
Price/Cash Flow 18.1x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FAES FARMA SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at